



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

The General Manager National Stock Exchange of India Ltd. Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex, Bandra (E) Mumbai - 400 051	The General Manager Bombay Stock Exchange Limited. Phiroze Jeejeebhoy Towers, Dalal Street Mumbai
---	--

IOLCP/CGC/2017
18 August 2017

Sub: Press Release for Financial Result for the quarter ended 30.06.2017

Dear Sirs,

Please find enclosed herewith press release regarding Financial Result for the quarter ended 30 June 2017 for your information.

Thanking you

Yours faithfully,
for IOL Chemicals and Pharmaceuticals Limited

[Krishan Singh]
Vice President & Company Secretary





For immediate release

Press Release

Impressive Results by IOL Chemicals and Pharmaceuticals Limited

**Revenue from operations (QoQ) increased by 29%,
Profit for the period increased from ₹ 0.71 crore to ₹ 2.98 crore**

IOL Chemicals and Pharmaceuticals Limited a leading manufacturer of bulk drugs and specialty chemicals posted an impressive performance for the first quarter ended 30 June 2017.

Revenue from operations increased by 29% during the quarter ended 30 June 2017 to ₹ 232.97 crore from ₹ 180.52 crore during the corresponding quarter of the previous year.

The Company has earned profit after tax during the quarter ended 30 June 2017 of ₹ 2.98 crore against ₹ 0.71 crore during the corresponding quarter of the previous year. The operating profit for the quarter ended 30 June 2017 went up to ₹ 27.62 crore as against operating profit of ₹ 25.73 crore reported in the corresponding quarter ended 30 June 2016.

The manufacturing capacity of the Ibuprofen has been increased from 6200 TPA to 7200 TPA after conversion of existing multipurpose plant.

The Ibuprofen manufacturing facilities have been approved by US Food and Drug Administration (USFDA), EDQM, WHO. The Company is already exporting its Ibuprofen in regulated & Emerging markets i.e. Europe, Latin America, Middle East, etc and with the approval from USFDA, the company is exploring its business in USA.

About IOL Chemicals and Pharmaceuticals Limited (IOLCP)

Company was established in 1986, listed on Bombay Stock Exchange (Code: 524164) and National Stock Exchange (Code: IOLCP) is India's one of the leading generic pharmaceutical company, and is significant player in the specialty chemicals space with world class facilities. IOLCP has wide presence across major therapeutic categories like, Pain Management, Anti-diabetic, Anti hypertensive, Anti Convulsants, etc.

IOLCP's product portfolio includes APIs; Ibuprofen, specialty chemicals such as Ethyl acetate, Iso Butyl Benzene (IBB), Mono Chloro Acetic Acid and Acetyl Chloride.

Company is world's only largest backward integrated Ibuprofen producer with an installed capacity of 7200TPA, manufacturing all intermediates stages and Key Starting Materials at



one location. The company has DSIR approved R&D which is fully equipped to validate existing processes.

The Central and State Government approved Effluent Treatment Plant (ETP) was set up with zero effluent discharge system alongwith 17 MW captive Co-Generation plant for self reliance.

IOLCP's overseas customers are spread out across several countries including Brazil, Argentina, China, Hungry, USA, Chile, Peru, Colombia, South Africa, Thailand, Australia, Netherlands, Iran and many other Middle East Countries. Products are sold primarily to Branded Generic formulators both in India & Overseas.

The company is continuous winner of National Energy Conservation award for 10 years. Company is an - ISO 9001:2008, ISO 14001:2004 and OHSAS 18001:2007

For more information on IOLCP, please visit <http://www.iolcp.com>

